Pharmabiz2h
European Union recommends approval of AstraZeneca’s Tagrisso for patients with unresectable EGFR-mutated lung cancer
Tagrisso improved patient outcomes in early-stage disease in the ADAURA phase III trial, Stage III, unresectable disease in the LAURA phase III trial, late-stage disease in the FLAURA phase III trial, ...
EuropaWire8m
AstraZeneca’s Tagrisso Receives EU Recommendation as First Targeted Therapy for Unresectable EGFR-Mutated Lung Cancer
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...
pharmaphorum4y
FDA grants fast review for AstraZeneca's Tagrisso in early-stage lung cancer
ADAURA tested Tagrisso (osimertinib) in patients with early-stage (1B, II and III) epidermal growth factor receptor-mutated (EGFR) non-small cell lung cancer (NSCLC) after complete tumour removal.
pharmaphorum8d
Tagrisso trial halted early after ‘overwhelming’ efficacy
AZ said that this would make Tagrisso the first EGFR inhibitor to ... The primary endpoint of the Phase III ADAURA trial is disease-free survival (DFS). The trial will continue to assess the ...
Hosted on MSN8mon
AstraZeneca’s Tagrisso regimen shows benefit in NSCLC trial
UK-based pharmaceutical company AstraZeneca has reported that the FLAURA2 Phase III clinical trial of Tagrisso (osimertinib) combined with chemotherapy showed a consistent benefit in prespecified ...
Eagle-Tribune1mon
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful ...
The global SAFFRON Phase III trial sponsored by AstraZeneca will further assess the TAGRISSO® plus ORPATHYS® combination versus platinum-based doublet chemotherapy in patients with EGFRm ...
London South East1mon
AstraZeneca upbeat on latest 'Tagrisso' trial results
(Alliance News) - AstraZeneca PLC on Thursday said that its cancer drug Tagrisso has been approved in the US for certain type of lung cancer. (Sharecast News) - AstraZeneca announced on Thursday ...